At present it is uncertain if prostate cancer due to germline mutations in HOXB13 is more or less aggressive than prostate cancer not due to such mutations and such clinical data will determine how such patients should be screened and managed. This evidence concerns the gene HOXB13 and Familial prostate cancer.